thiophosphoric acid O,O',S-tripropyl ester | 64008-12-4

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机硫代磷化合物
• 英文名称: thiophosphoric acid O,O',S-tripropyl ester
• 英文别名: Thiophosphorsaeure-O,O',S-tripropylester；O.O.S-Tripropyl-thiophosphat；1-[Propoxy(propylsulfanyl)phosphoryl]oxypropane
• CAS: 64008-12-4
• 化学式: C₉H₂₁O₃PS
• 分子量: 240.304
• InChiKey: UBAGKIXMCYKMEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  O,O,O-tripropyl phosphorothioate 、 1-碘代丙烷 生成 thiophosphoric acid O,O',S-tripropyl ester
  参考文献：
  名称：

  Pistschimuka, Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1912, vol. 44, p. 1439,1442

  摘要：

  DOI：

文献信息

• Flame retardant polyphenylene oxide thermoplastics
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0175281A2

  公开（公告）日：1986-03-26

  Flame retardant blends of polyphenylene oxide and styrene resin are provided as a result of the use of a minor amount of a triorganothiophosphate.

  由于使用了少量的三有机硫代磷酸酯，提供了聚苯醚和苯乙烯树脂的阻燃混合物。
• LUBRICANT COMPOSITION AND DRIVING FORCE TRANSMITTING SYSTEM USING SAME
  申请人：Nippon Oil Corporation

  公开号：EP1816183A1

  公开（公告）日：2007-08-08

  The invention provides a lubricating oil composition comprising a lubricating base oil, a phosphorus compound and at least one organic acid salt selected from among alkaline earth metal sulfonates, alkaline earth metal phenates and alkaline earth metal salicylates, wherein the contents of the phosphorus compound and organic acid salt satisfy the conditions represented by the following formulas (1) to (3). In formulas (1)-(3), W(P) represents the content of phosphorus compound, in terms of phosphorus element, based on the total amount of the lubricating oil composition, and W(M) represents the content of organic acid salt content, in terms of alkaline earth metal elements, based on the total amount of the lubricating oil composition.

  本发明提供了一种润滑油组合物，该组合物由润滑基础油、磷化合物和至少一种选自碱土金属磺酸盐、碱土金属苯酸盐和碱土金属水杨酸盐的有机酸盐组成，其中磷化合物和有机酸盐的含量满足以下公式(1)至(3)所代表的条件。在公式(1)至(3)中，W(P)表示磷化合物的含量（以磷元素计），以润滑油组合物的总量为基础；W(M)表示有机酸盐的含量（以碱土金属元素计），以润滑油组合物的总量为基础。
• SKIN FIBROSIS TREATMENT AGENT
  申请人：Nitto Denko Corporation

  公开号：EP3536343A1

  公开（公告）日：2019-09-11

  The present invention relates to: a carrier for delivering a retinoid-containing substance used by extracellular-matrix-producing cells in the skin; a skin fibrosis treatment agent using said carrier; a preparation kit for said treatment agent; a production method for said carrier; and a production method for said treatment agent.

  本发明涉及：一种用于输送皮肤细胞外基质生成细胞所使用的含维甲酸物质的载体；一种使用所述载体的皮肤纤维化治疗剂；一种用于所述治疗剂的制备试剂盒；一种用于所述载体的生产方法；以及一种用于所述治疗剂的生产方法。
• Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues
  申请人：QBI ENTERPRISES LTD.

  公开号：US10059942B2

  公开（公告）日：2018-08-28

  Disclosed herein are double-stranded RNA nucleic acid molecules, which include at least one pyrazolotriazine nucleotide analog and have been modified to exhibit one of the following, increased on-target activity, increased target specificity, enhanced nuclease stability, reduced off target activity and/or reduced immunogenicity when compared to an unmodified or similarly modified dsRNA; pharmaceutical compositions comprising such molecules and methods of use thereof in therapy.

  本文公开了双链 RNA 核酸分子，其中包括至少一种吡唑三嗪核苷酸类似物，与未经修饰或类似修饰的 dsRNA 相比，经过修饰的双链 RNA 核酸分子表现出以下特征之一：靶上活性增强、靶特异性增强、核酸酶稳定性增强、靶外活性降低和/或免疫原性降低；包含此类分子的药物组合物及其用于治疗的方法。
• Modulation of HSP47 expression
  申请人：NITTO DENKO CORPORATION

  公开号：US10093923B2

  公开（公告）日：2018-10-09

  Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

  本文提供了用于调节靶基因，特别是热休克蛋白 47（hsp47）表达的组合物、方法和试剂盒。这些组合物、方法和试剂盒可包括调节编码 hsp47 的基因（例如编码人类 hsp47 的基因）的核酸分子（例如短干扰核酸 (siNA)、短干扰 RNA (siRNA)、双链 RNA (dsRNA)、微 RNA (miRNA) 或短发夹 RNA (shRNA)）。本文公开的组合物和方法还可用于治疗与 hsp47 相关的病症和疾病，如肝脏纤维化、肺纤维化、腹膜纤维化和肾脏纤维化。